Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes ...

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years ...

Diabetes patients on dulaglutide (Trulicity) had better glycemic control and more weight loss if they switched to tirzepatide ...

The study, led by Dr Luca Busetto from the University of Padova in Italy and colleagues from Eli Lilly and Company that ...

Taking tirzepatide drug once a week may produce clinically meaningful and sustained weight loss for at least 3 years in adults with overweight or obesity who do not have diabetes, according to new ...

Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...

BMO Capital Markets downgraded Novo Nordisk (NYSE:NVO) to “Market Perform” from “Outperform” and cut its price target to $64, saying the Danish drugmaker’s early lead in the obesity drug market is ...

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the European Congress on Obesity (ECO) in Malaga, Spain, reveal that the drug ...